Q1 2027 Shaily Engineering Plastics Ltd Earnings Call Transcript
Key Points
- Healthcare segment revenue surged 85% YoY to INR 142 crores, becoming the largest business segment and contributing 51% of consolidated revenue.
- EBITDA grew 18% YoY to INR 83 crores with margin expansion of 120 bps to 29.7%, while PAT increased 17% to INR 48 crores.
- Secured two new platform projects in healthcare and received orders for injector pen supplies following regulatory approvals for semaglutide in Canada and Brazil.
- Appointed dedicated heads of business development for Europe and North America, enhancing prospects for partnerships with major global pharmaceutical companies.
- Industrial segment grew 25% YoY, with new customer additions and business confirmations in consumer electronics, automotive, and appliance sectors.
- New 25 million pen injector capacity is on track to be operational by end of September, with plans to achieve 80%+ efficiency at the supplier before shipping to avoid ramp-up issues.
- Company is confident of exceeding its full-year guidance of 36 million pens, driven by strong demand and improving operational efficiencies.
- Expanding into high-value healthcare niches like emergency use autoinjectors, reusable autoinjectors, and on-body injectors, with the reusable device set to be showcased at CPHI.
- Consumer electronics business is progressing with commercial supplies started and five new components awarded from a new customer, targeting $10 million revenue within 24-30 months.
- Semiconductor tray business is expected to start contributing revenue from Q4 FY27, with a specialized product offering and less than a dozen global competitors.
- Consumer segment revenue declined 24% YoY to INR 116 crores due to soft demand in home furnishings across Europe and the US.
- Gross margin declined sequentially due to increased commodity prices, elevated freight costs, and premium freight incidents from geopolitical tensions in West Asia.
- Machine utilization remains low at 50.2%, indicating significant idle capacity despite gradual improvement.
- New production line for pen injectors is still facing efficiency issues, with only a 9% speed improvement and additional equipment pending, limiting near-term output.
- Export share dropped to 58% from 76% YoY, reflecting a shift in revenue mix and potential over-reliance on domestic pharma customers for healthcare exports.
- The company faces potential pricing pressure from Chinese competitors offering copycat products at lower prices, though management downplays the threat.
- Uncertainty in the consumer segment persists, with management expecting no growth in the current year and unable to provide a clear outlook.
- The UK subsidiary experienced a revenue drop due to timing issues in milestone invoicing, which may affect quarterly results.
- The Abu Dhabi facility is still in early stages, with only 50-55% capacity commitments secured and production not expected until end of FY28.
- The company is not providing specific guidance on consumer electronics or semiconductor revenue timelines, creating uncertainty for investors.
Ladies and Gentlemen, good day and welcome to the Q1 FY27 Earnings Conference Call-off Shaily Engineering Plastic Ltd. (Operator Instructions)
I would now like to hand the conference over to Mr. Amit Sanghvi, Managing Director of Sherry Engineering Plastics Limited.
Thank you and over to you sir.
Thank you very much.
Good afternoon. Everyone and thank you for joining Shelley Engineering Plastics earnings call for quarter one FY27.
I am joined today by Sanjay Shah, our Chief Strategy Officer and SG&A, our Investor Relations Advisor. I hope everyone has had the opportunity to review our financial results and investor presentation, which have been uploaded on the stock exchange as well as the company's website.
The global operating environment remains challenging. In the quarter with continued uncertainty arising from the geopolitical situation in West Asia and its wider impact on supply chain as well as commodity markets. This
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
